in general, bio manufacturers face challenges in the fill/finish step when dealing with biologics. Particularly the management of time when vaccines are out of controlled storage. Hence, IDT being close to CSL is another leading advantage moving forward.
fill/finish operations are predominantly outsourced to create additional capacity and expediate expansions and effective management. it is critical to the scale up of manufacturing.
in general, bio manufacturers face challenges in the fill/finish...
-
- There are more pages in this discussion • 611 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.66M | |||
| Open | High | Low | Value | Volume |
| 10.8¢ | 11.0¢ | 10.5¢ | $53.79K | 489.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 46925 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 111400 | 3 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IDT (ASX) Chart |